The selective α1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease

Synapse

Volumn 64, Issue 2, 2010, Pages 117-126

  Buck, Kerstin ^a   Ferger, Boris ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

6 Hydroxydopamine; Amantadine; Cirazoline; Idazoxan; Microdialysis; Propranolol

Indexed keywords

2 [[BETA (4 HYDROXYPHENYL)ETHYL]AMINOMETHYL] 1 TETRALONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; CIRAZOLINE; IDAZOXAN; LEVODOPA; OXIDOPAMINE; PROPRANOLOL; UNCLASSIFIED DRUG; 2 [2 (4 HYDROXYPHENYL)ETHYLAMINOMETHYL]TETRALONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TETRALIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENDRITIC SPINE; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DYSKINESIA; EXPLORATORY BEHAVIOR; IN VIVO STUDY; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; ANIMAL; BRAIN; CEREBROSPINAL FLUID; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; METABOLISM; PARKINSONISM; PLASMA; RANDOMIZATION; WISTAR RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CEREBROSPINAL FLUID; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; IDAZOXAN; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PLASMA; PROPRANOLOL; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; TETRALONES;

EID: 72449124213     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20709     Document Type: Article

References (38)

1. Ahlskog JE, Muenter MD. 2001. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458.
2. Alexander SP, Mathie A, Peters JA. 2005. Guide to receptors and channels, 1st ed. (2005 revision). Br J Pharmacol 144(Suppl 1): S1-128. (Pubitemid 44289011)
3. Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin JP. 2004. 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 20:3073-3084. (Pubitemid 40007302)
4. Belujon P, Bezard E, Taupignon A, Bioulac B, Benazzouz A. 2007. Noradrenergic modulation of subthalamic nucleus activity: Behavioral and electrophysiological evidence in intact and 6-hydroxydopamine- lesioned rats. J Neurosci 27:9595-9606. (Pubitemid 47492192)
5. Buck K, Ferger B. 2008. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents L-DOPA-induced dyskinesia: A bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiol Dis 29:210-220.
6. Buck K, Ferger B. 2009. Comparison of intrastriatal administration of noradrenaline and L-DOPA on dyskinetic movements: A bilateral reverse in vivo microdialysis study in 6-hydroxydopaminelesioned rats. Neuroscience 159:16-20.
7. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U. 1994. International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136. (Pubitemid 24185147)
8. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. 1996. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 46:1548-1551. (Pubitemid 26185769)
9. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. 2006. Role of striatal L-Dopa in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96:1718-1727. (Pubitemid 43351629)
10. Cenci MA. 2007. Dopamine dysregulation of movement control in L-Dopa-induced dyskinesia. Trends Neurosci 30:236-243. (Pubitemid 46654236)
11. Cenci MA, Lee CS, Bjorklund A. 1998. L-Dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphinand glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706. (Pubitemid 28362576)
12. Dekundy A, Lundblad M, Danysz W, Cenci MA. 2007. Modulation of L-Dopa-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model. Behav Brain Res 179:76-89. (Pubitemid 46441485)
13. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. 2001. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16:642-650. (Pubitemid 36040843)
14. Gomez-Mancilla B, Bedard PJ. 1993. Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418-427. (Pubitemid 23292096)
15. Grondin R, Hadj TA, Doan VD, Ladure P, Bedard PJ. 2000. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361:181-186. (Pubitemid 30062450)
16. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. 1999. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14:744-753. (Pubitemid 29509616)
17. Hill MP, Brotchie JM. 1999. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoaminedepleted rat. Br J Pharmacol 128:1577-1585.
18. Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H. 2004. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 310:386-394.
19. Jenner P. 2008a. Molecular mechanisms of L-Dopa-induced dyskinesia. Nat Rev Neurosci 9:665-677.
20. Jenner P. 2008b. Preventing and controlling dyskinesia in Parkinson's disease - A view of current knowledge and future opportunities. Mov Disord 23(Suppl 3):S585-S598.
21. Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM. 2005. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Exp Neurol 191:243-250. (Pubitemid 40092867)
22. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. 2005. Levodopadyskinesia incidence by age of Parkinson's disease onset. Mov Disord 20:342-344. (Pubitemid 40613295)
23. Lin JH. 2008. CSF as a surrogate for assessing CNS exposure: An industrial perspective. Curr Drug Metab 9:46-59.
24. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. 2002. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132. (Pubitemid 35478015)
25. Mathe JM, Nomikos GG, Hildebrand BE, Hertel P, Svensson TH. 1996. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol 309:1-11. (Pubitemid 26253010)
26. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. 2000. The evolution and origin of motor complications in Parkinson's disease. Neurology 55:S13-S20.
27. Pan WH, Yang SY, Lin SK. 2004. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex. Synapse 53:44-52. (Pubitemid 38703004)
28. Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP. 2009. The sigma-1 antagonist BMY-14802 inhibits L-Dopainduced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl) 204:743-754.
29. Paul P, Lahaye C, Delagrange P, Nicolas JP, Canet E, Boutin JA. 1999. Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther 290:334-340. (Pubitemid 29302340)
30. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. San Diego: Academic Press.
31. Rascol O. 2000. Medical treatment of levodopa-induced dyskinesias. Ann Neurol 47:S179-S188.
32. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. 2000. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa, 056 Study Group. N Engl J Med 342:1484-1491. (Pubitemid 30318272)
33. Rascol O, Arnulf I, Peyro-Saint PH, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y. 2001. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 16:708-713. (Pubitemid 36040852)
34. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. 2003. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 18:872-883. (Pubitemid 37021161)
35. Sommermeyer H, Frielingsdorf J, Knorr A. 1995. Effects of prazosin on the dopaminergic neurotransmission in rat brain. Eur J Pharmacol 276:267-270.
36. Stocchi F, Tagliati M, Olanow CW. 2008. Treatment of levodopainduced motor complications. Mov Disord 23(Suppl 3):S599-S612.
37. Verhagen Metman L, Del DP, LePoole K, Konitsiotis S, Fang J, Chase TN. 1999. Amantadine for levodopa-induced dyskinesias: A 1-year follow-up study. Arch Neurol 56:1383-1386. (Pubitemid 29519855)
38. Visanji NP, Fox SH, Johnston TH, Millan MJ, Brotchie JM. 2009. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther 328:276-283.